Childhood cancers: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• ABL1 2
• NF1 12
• HER2 25
• PI3K 5
• PD-L1 13
• AKT 1
• CDK4/6 7
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• PSMA 20
• KMT2A 12
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• CD38 5
• EZH2 0
• RAS 1
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 941 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

  NCT02992964· The Hospital for Sick Children· Updated 5 Nov 2026

  “Withdrawal of drug supply/funding”Registry text, quoted unchanged. Source

• Withdrawn

  xPedite: A Study to Expedite DIPG and DMG Research

  NCT06140719· xCures· Updated 2 Nov 2026

  “Protocol termination”Registry text, quoted unchanged. Source

• Suspended

  PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

  NCT06639607· Washington University School of Medicine· Updated 30 Oct 2026

  “Drugs/Equipment Unavailable”Registry text, quoted unchanged. Source

• Suspended

  A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  NCT05691478· National Cancer Institute (NCI)· Updated 27 Oct 2026

  “Other - Extend the observation period for current patients”Registry text, quoted unchanged. Source

• Suspended

  Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

  NCT05756660· Children's Hospital Medical Center, Cincinnati· Updated 22 Oct 2026

  “This study will be closing at CCHMC and may be transferred to a principal investigator at another insitutiton.”Registry text, quoted unchanged. Source

• Terminated

  Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

  NCT03904862· Pediatric Brain Tumor Consortium· Updated 19 Oct 2026

  “The decision to permanently close PBTC-053 was made following communication from the NCI that the PBTC grant will not be extended beyond March 31, 2026.”Registry text, quoted unchanged. Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Updated 16 Oct 2026

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”Registry text, quoted unchanged. Source

• Suspended

  Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

  NCT07052383· Tcelltech Inc.· Updated 14 Oct 2026

  “Data update in progress.”Registry text, quoted unchanged. Source

• Terminated

  Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors

  NCT04485416· University of California, Davis· Updated 9 Oct 2026

  “PI discretion; suspended while CAPA is reviewed”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Medically Tailored Meals for Kids

  NCT06814795· UNC Lineberger Comprehensive Cancer Center· Source

• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

  NCT04394858· National Cancer Institute (NCI)· Source

• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

  NCT05333458· National Cancer Institute (NCI)· Source

• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

  NCT05372640· National Cancer Institute (NCI)· Source

• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

  NCT03871257· National Cancer Institute (NCI)· Source

• Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

  NCT00044304· National Institutes of Health Clinical Center (CC)· Source

• A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

  NCT05621291· National Cancer Institute (NCI)· Source

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· National Cancer Institute (NCI)· Source

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 30
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 86
• Immunohistochemistry 197
• Liquid Biopsy 24
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 518
• Machine Learning 66
• Deep Learning 25
• Cohort Studies 327
• Genome-Wide Association Study 22

See which targets of this disease your abstract mentions, and go to the people working on them.